Pharmafile Logo

GMOs

- PMLiVE

BioNTech on course to produce three billion doses of Pfizer-partnered COVID-19 vaccine in 2021

BioNTech’s CEO Ugur Sahin said increase in manufacturing will allow for this target to be met

- PMLiVE

Pfizer’s COVID-19 vaccine yields $3.5bn in first quarter sales

Full-year guidance for BioNTech-partnered vaccine increased to $26bn

- PMLiVE

Novavax is close to finalising a COVID-19 vaccine supply deal with the EU

Reuters reported that the company is planning to send doses to Europe before the end of the year

- PMLiVE

Moderna agrees to supply Gavi with 500 million doses for COVAX

Moderna will deliver an initial 34 million doses to COVAX in the fourth quarter of 2021

How Patient Advocacy Can Positively Disrupt Healthcare

Seth Rotberg, Patient Recruitment Manager at WEGO Health & Co-Founder of Our Odyssey, shares his views on how to empower rare disease patients, improve clinical trials, and move towards a...

Impetus Digital

Leaders in Pharma: Danielle Portnik

In this episode of Impetus Digital's Leaders in Pharma podcast, I sit down with Danielle Portnik. She is currently the Regional Business Director for International with Ambry Genetics.

Impetus Digital

- PMLiVE

Versiti launches test for vaccine-related blood clot issues

Launch follows reports of very rare blood clots connected to J&J's vaccine

- PMLiVE

Pfizer CEO says oral COVID-19 pill could be ready by the end of the year

Company initiated a phase 1 study of the drug last month

- PMLiVE

EU moves forward with legal action against AZ over vaccine supply issues

Legal proceeding launched on the basis of 'breaches of the advanced purchase agreement'

- PMLiVE

WHO to review Moderna’s COVID-19 vaccine for emergency use listing this week

WHO is also due to review vaccines from Sinopharm and Sinovac for possible EUAs

- PMLiVE

J&J resumes US rollout of single-dose COVID-19 vaccine

CDC and FDA recommended pause be lifted after ‘rigorous review’ of very rare blood clots

- PMLiVE

Single dose of COVID-19 vaccines ‘significantly’ reduces infections

Infections fell by 65% after first dose of AZ/Oxford or Pfizer/BioNTech vaccines

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links